{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:32Z","timestamp":1792511372579,"version":"4.5.0"},"reference-count":29,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: This investigation evaluated the predictive and prognostic efficacy of the newly developed global immune-nutrition-inflammation index (GINI) in patients with grade 4 adult-type diffuse gliomas, comparing it with other established indices such as the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV). Method: A retrospective cohort included 198 patients diagnosed with isocitrate dehydrogenase (IDH)-mutant gr4 (grade 4) astrocytoma and IDH-wt (wilde-type) glioblastoma (GBM) gr4 treated with surgical resection, radiotherapy, and temozolomide. Patients were stratified into two groups based on their GINI values: low GINI (&lt;5815) and high GINI (\u22655815). The primary endpoint was overall survival (OS). Results: High GINI was significantly associated with older age, poor performance status, multifocal tumors, and higher SII, SIRI, and PIV values (p &lt; 0.005). The GINI demonstrated strong correlations with SII (r = 0.694), SIRI (r = 0.516), and PIV (r = 0.657) (p &lt; 0.001). Patients with high GINI exhibited poorer OS (5.0 vs. 17.0 months) and PFS (5.0 vs. 13.0 months) in comparison to those with low GINI. Kaplan\u2013Meier survival analysis revealed significantly prolonged OS and PFS among patients with low GINI (p &lt; 0.001). Multivariate analysis identified high GINI as an independent negative risk factor for both PFS and OS. Conclusions: GINI is a robust predictor of clinical outcomes in IDH-mutant gr4 astrocytoma and IDH-wt GBM gr4, highlighting the crucial impact of nutrition and cancer cachexia. It shows superior prognostic value relative to the SII, SIRI, and PIV.<\/jats:p>","DOI":"10.3390\/curroncol31090372","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T03:57:06Z","timestamp":1724817426000},"page":"5027-5039","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Unraveling the Predictive Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) on Survival Outcomes in Patients with Grade 4 Adult-Type Diffuse Gliomas"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-9825","authenticated-orcid":false,"given":"Asim Armagan","family":"Aydin","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Antalya Education and Research Hospital, Health Science University, 07100 Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan Oguz","family":"Yuceer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Grochans, S., Cybulska, A.M., Simi\u0144ska, D., Korbecki, J., Kojder, K., Chlubek, D., and Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme\u2013Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14102412"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-018-03065-z","article-title":"Association of Patterns of Care, Prognostic Factors, and Use of Radiotherapy\u2013Temozolomide Therapy with Survival in Patients with Newly Diagnosed Glioblastoma: A French National Population-Based Study","volume":"142","author":"Zouaoui","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1515\/med-2019-0031","article-title":"Analysis of the Factors Affecting the Prognosis of Glioma Patients","volume":"14","author":"Wang","year":"2019","journal-title":"Open Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in Isocitrate Dehydrogenase 1\u2014Mutated Advanced Glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","article-title":"A Review of Glioblastoma Immunotherapy","volume":"151","author":"Medikonda","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for Glioblastoma: The Promise of Combination Strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41584-022-00905-1","article-title":"Inflammation and DNA Damage: Cause, Effect or Both","volume":"19","author":"Pezone","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., and Tang, H. (2022). Chronic Inflammation, Cancer Development and Immunotherapy. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1040163"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.trecan.2023.02.001","article-title":"Cell Death, Therapeutics, and the Immune Response in Cancer","volume":"9","author":"Ruffell","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the Immune Response to Cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e38245","DOI":"10.1097\/MD.0000000000038245","article-title":"Targeting Inflammation in Glioblastoma: An Updated Review from Pathophysiology to Novel Therapeutic Approaches","volume":"103","author":"Alorfi","year":"2024","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Guo, X., Jiao, H., Zhang, T., and Zhang, Y. (2022). Pre-Treatment and Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Prognostic Value of Glioblastoma: A Meta-Analysis. Brain Sci., 12.","DOI":"10.3390\/brainsci12050675"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.wneu.2023.04.086","article-title":"Prognostic Value of the Platelet-Lymphocyte Ratio for Glioblastoma: A Systematic Review","volume":"175","author":"Bispo","year":"2023","journal-title":"World Neurosurg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1007\/s10072-022-06158-w","article-title":"The Prognostic Value of the Preoperative Inflammatory Index on the Survival of Glioblastoma Patients","volume":"43","author":"Shi","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yang, C., Hu, B.-W., Tang, F., Zhang, Q., Quan, W., Wang, J., Wang, Z.-F., Li, Y.-R., and Li, Z.-Q. (2022). Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11247514"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Duan, X., Yang, B., Zhao, C., Tie, B., Cao, L., and Gao, Y. (2023). Prognostic Value of Preoperative Hematological Markers in Patients with Glioblastoma Multiforme and Construction of Random Survival Forest Model. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10889-0"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jarmuzek, P., Kozlowska, K., Defort, P., Kot, M., and Zembron-Lacny, A. (2023). Prognostic Values of Systemic Inflammatory Immunological Markers in Glioblastoma: A Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15133339"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12957-022-02588-0","article-title":"Prognostic Significance of Preoperative Systemic Inflammation Response Index in Newly Diagnosed Glioblastoma Patients Underwent Gross Total Resection: A Propensity Score Matching Analysis","volume":"20","author":"Wang","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, C., Lan, T., Wang, Y., Huang, W.-H., Li, S.-M., Li, J., Li, F.-P., Li, Y.-R., Wang, Z.-F., and Li, Z.-Q. (2022). Cumulative Scoring Systems and Nomograms for Predicating Survival in Patients With Glioblastomas: A Study Based on Peripheral Inflammatory Markers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.716295"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e33050","DOI":"10.1097\/MD.0000000000033050","article-title":"Association between Systemic Immune-Inflammation Index (SII) and Survival Outcome in Patients with Primary Glioblastoma","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1346094","DOI":"10.1155\/2022\/1346094","article-title":"Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide","volume":"2022","author":"Topkan","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tcr.2020.01.57","article-title":"Serum Albumin Levels and Serum Albumin-Globulin Ratio Are Associated with Poor Prognosis in Glioblastoma","volume":"9","author":"Yalikun","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e20927","DOI":"10.1097\/MD.0000000000020927","article-title":"Prognostic Significance of Preoperative Serum Albumin, Albumin-to-Globulin Ratio, and Prognostic Nutritional Index for Patients with Glioma","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12957-021-02253-y","article-title":"Prognostic Value of the C-Reactive Protein to Albumin Ratio in Colorectal Cancer: An Updated Systematic Review and Meta-Analysis","volume":"19","author":"Liao","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Topkan, E., Selek, U., Pehlivan, B., Kucuk, A., Ozturk, D., Ozdemir, B.S., Besen, A.A., and Mertsoylu, H. (2023). The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. Cancers, 15.","DOI":"10.3390\/cancers15184512"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/372\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:44:02Z","timestamp":1760111042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090372"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090372","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}